Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 59 | 2024 | 3602 | 6.470 |
Why?
|
Myelodysplastic Syndromes | 32 | 2024 | 1394 | 6.240 |
Why?
|
Hematopoietic Stem Cell Transplantation | 18 | 2023 | 5649 | 1.460 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 1547 | 1.330 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2022 | 495 | 1.160 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2023 | 92 | 1.050 |
Why?
|
Myeloproliferative Disorders | 4 | 2022 | 609 | 0.710 |
Why?
|
Azepines | 2 | 2019 | 330 | 0.710 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 11712 | 0.690 |
Why?
|
Bone Marrow | 6 | 2023 | 2912 | 0.670 |
Why?
|
Azacitidine | 5 | 2023 | 334 | 0.650 |
Why?
|
Remission Induction | 15 | 2022 | 2392 | 0.650 |
Why?
|
Mutation | 17 | 2024 | 29932 | 0.640 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2023 | 929 | 0.640 |
Why?
|
Hematologic Neoplasms | 4 | 2021 | 1895 | 0.630 |
Why?
|
Immunoconjugates | 2 | 2022 | 949 | 0.590 |
Why?
|
SEER Program | 7 | 2022 | 1530 | 0.580 |
Why?
|
Gastritis | 1 | 2019 | 198 | 0.580 |
Why?
|
Glutarates | 1 | 2018 | 244 | 0.560 |
Why?
|
Pyrimidines | 4 | 2020 | 3016 | 0.560 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2023 | 640 | 0.550 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2018 | 251 | 0.550 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1454 | 0.550 |
Why?
|
Anemia | 2 | 2023 | 1511 | 0.540 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2020 | 685 | 0.530 |
Why?
|
Core Binding Factors | 2 | 2022 | 29 | 0.520 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 180 | 0.510 |
Why?
|
Antifungal Agents | 1 | 2020 | 749 | 0.500 |
Why?
|
Neoplasms, Second Primary | 4 | 2021 | 1056 | 0.490 |
Why?
|
Drugs, Investigational | 1 | 2017 | 214 | 0.490 |
Why?
|
RNA Splicing | 1 | 2019 | 915 | 0.490 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 2803 | 0.470 |
Why?
|
Niacinamide | 1 | 2016 | 414 | 0.460 |
Why?
|
beta-Thalassemia | 1 | 2016 | 235 | 0.450 |
Why?
|
Cytarabine | 8 | 2019 | 696 | 0.450 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.430 |
Why?
|
Asparaginase | 2 | 2024 | 240 | 0.420 |
Why?
|
Humans | 115 | 2024 | 760621 | 0.420 |
Why?
|
Protein Kinase Inhibitors | 4 | 2017 | 5643 | 0.400 |
Why?
|
Recurrence | 9 | 2023 | 8482 | 0.400 |
Why?
|
Aged | 51 | 2024 | 169152 | 0.370 |
Why?
|
Neoplasms | 8 | 2023 | 22072 | 0.360 |
Why?
|
Arthritis, Experimental | 1 | 2012 | 291 | 0.340 |
Why?
|
Drug Discovery | 1 | 2017 | 1057 | 0.320 |
Why?
|
Aged, 80 and over | 24 | 2024 | 58995 | 0.320 |
Why?
|
Middle Aged | 53 | 2024 | 220352 | 0.310 |
Why?
|
Translocation, Genetic | 4 | 2021 | 1388 | 0.310 |
Why?
|
Treatment Outcome | 19 | 2023 | 65017 | 0.280 |
Why?
|
Transplantation Conditioning | 4 | 2022 | 1588 | 0.280 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9185 | 0.270 |
Why?
|
Prognosis | 15 | 2024 | 29658 | 0.270 |
Why?
|
Eosinophilia | 2 | 2022 | 559 | 0.270 |
Why?
|
Thiazoles | 1 | 2013 | 1511 | 0.270 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2021 | 452 | 0.260 |
Why?
|
Male | 54 | 2024 | 359744 | 0.250 |
Why?
|
Young Adult | 25 | 2024 | 58741 | 0.250 |
Why?
|
Quality of Life | 10 | 2023 | 13308 | 0.240 |
Why?
|
Transplantation, Homologous | 7 | 2022 | 4810 | 0.240 |
Why?
|
Incidence | 9 | 2024 | 21392 | 0.230 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 17790 | 0.230 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10181 | 0.230 |
Why?
|
Adult | 43 | 2024 | 219994 | 0.230 |
Why?
|
Osteoarthritis | 1 | 2012 | 1055 | 0.230 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13630 | 0.230 |
Why?
|
Female | 52 | 2024 | 391270 | 0.220 |
Why?
|
Blast Crisis | 2 | 2022 | 101 | 0.220 |
Why?
|
Salvage Therapy | 3 | 2018 | 1268 | 0.210 |
Why?
|
Protein-Arginine N-Methyltransferases | 2 | 2023 | 131 | 0.210 |
Why?
|
Immunotherapy | 4 | 2022 | 4642 | 0.210 |
Why?
|
Idarubicin | 2 | 2019 | 59 | 0.210 |
Why?
|
Disease-Free Survival | 8 | 2023 | 6828 | 0.200 |
Why?
|
Retrospective Studies | 24 | 2024 | 80372 | 0.200 |
Why?
|
Leukocytosis | 2 | 2020 | 251 | 0.200 |
Why?
|
Bone Marrow Examination | 1 | 2021 | 155 | 0.190 |
Why?
|
Cancer Care Facilities | 1 | 2024 | 424 | 0.190 |
Why?
|
Anemia, Sideroblastic | 1 | 2022 | 109 | 0.180 |
Why?
|
Cholecystitis | 1 | 2021 | 181 | 0.180 |
Why?
|
Acute Disease | 5 | 2019 | 7269 | 0.180 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 96 | 0.180 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2022 | 1596 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 316 | 0.170 |
Why?
|
Survival Analysis | 8 | 2021 | 10182 | 0.170 |
Why?
|
Erythroid Cells | 1 | 2021 | 235 | 0.170 |
Why?
|
Hematology | 1 | 2023 | 241 | 0.170 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 117 | 0.170 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2021 | 342 | 0.160 |
Why?
|
Survival Rate | 5 | 2018 | 12808 | 0.160 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 381 | 0.160 |
Why?
|
Enzyme Inhibitors | 2 | 2022 | 3726 | 0.160 |
Why?
|
Methyltransferases | 1 | 2022 | 374 | 0.160 |
Why?
|
Spliceosomes | 1 | 2019 | 129 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 466 | 0.160 |
Why?
|
Staurosporine | 1 | 2019 | 242 | 0.160 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2017 | 39 | 0.150 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2013 | 4024 | 0.150 |
Why?
|
Graft vs Host Disease | 3 | 2022 | 3025 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2022 | 611 | 0.150 |
Why?
|
Pyridines | 2 | 2021 | 2879 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 8056 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 424 | 0.140 |
Why?
|
Body Mass Index | 2 | 2023 | 12914 | 0.140 |
Why?
|
Biopsy | 2 | 2021 | 6771 | 0.140 |
Why?
|
Terminal Care | 2 | 2021 | 1758 | 0.140 |
Why?
|
Adolescent | 17 | 2024 | 87810 | 0.140 |
Why?
|
Off-Label Use | 1 | 2018 | 184 | 0.140 |
Why?
|
Nuclear Proteins | 3 | 2021 | 5791 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 695 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6315 | 0.130 |
Why?
|
Risk Factors | 10 | 2024 | 74359 | 0.130 |
Why?
|
Cerebrospinal Fluid | 1 | 2018 | 544 | 0.130 |
Why?
|
Erythrocyte Indices | 1 | 2016 | 145 | 0.130 |
Why?
|
Osteosarcoma | 2 | 2018 | 897 | 0.130 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.130 |
Why?
|
Thrombotic Microangiopathies | 1 | 2017 | 124 | 0.130 |
Why?
|
Blood Cell Count | 1 | 2016 | 397 | 0.130 |
Why?
|
Anemia, Macrocytic | 1 | 2015 | 54 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39261 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9276 | 0.120 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5251 | 0.120 |
Why?
|
Mitoxantrone | 3 | 2019 | 149 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2919 | 0.120 |
Why?
|
Abdominal Pain | 1 | 2021 | 1063 | 0.120 |
Why?
|
Eligibility Determination | 1 | 2018 | 421 | 0.120 |
Why?
|
Alternative Splicing | 1 | 2019 | 1091 | 0.120 |
Why?
|
Anilides | 1 | 2017 | 409 | 0.120 |
Why?
|
Hospice Care | 1 | 2021 | 692 | 0.120 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 1007 | 0.120 |
Why?
|
Sarcoma, Myeloid | 1 | 2014 | 51 | 0.120 |
Why?
|
Karyotyping | 1 | 2016 | 1171 | 0.120 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 521 | 0.120 |
Why?
|
Urate Oxidase | 1 | 2014 | 31 | 0.120 |
Why?
|
Leukemia | 2 | 2024 | 1520 | 0.110 |
Why?
|
Sulfonamides | 2 | 2022 | 1977 | 0.110 |
Why?
|
Gene Frequency | 2 | 2018 | 3615 | 0.110 |
Why?
|
Lymphoma | 1 | 2023 | 1898 | 0.110 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2014 | 228 | 0.110 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12531 | 0.110 |
Why?
|
Central Nervous System | 2 | 2018 | 1334 | 0.110 |
Why?
|
Etoposide | 3 | 2019 | 630 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 3 | 2021 | 3164 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 209 | 0.110 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15757 | 0.110 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2021 | 4555 | 0.110 |
Why?
|
Procollagen N-Endopeptidase | 1 | 2012 | 19 | 0.100 |
Why?
|
Sulfur Radioisotopes | 1 | 2012 | 113 | 0.100 |
Why?
|
Age Factors | 5 | 2018 | 18416 | 0.100 |
Why?
|
Phosphoproteins | 1 | 2021 | 2440 | 0.100 |
Why?
|
Motivation | 1 | 2022 | 1993 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2514 | 0.100 |
Why?
|
Stem Cell Transplantation | 2 | 2018 | 1599 | 0.100 |
Why?
|
Boston | 3 | 2021 | 9280 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6544 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1299 | 0.100 |
Why?
|
Maximum Tolerated Dose | 3 | 2019 | 877 | 0.100 |
Why?
|
Blood Transfusion | 1 | 2018 | 1328 | 0.100 |
Why?
|
United States | 8 | 2023 | 72461 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1864 | 0.100 |
Why?
|
Splenosis | 1 | 2011 | 4 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1480 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8552 | 0.090 |
Why?
|
Risk Assessment | 4 | 2024 | 24123 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2022 | 2506 | 0.090 |
Why?
|
Adaptation, Psychological | 4 | 2022 | 2628 | 0.090 |
Why?
|
Piperazines | 1 | 2021 | 2525 | 0.090 |
Why?
|
ADAM Proteins | 1 | 2012 | 240 | 0.090 |
Why?
|
Leukapheresis | 2 | 2020 | 134 | 0.090 |
Why?
|
Health Care Costs | 1 | 2023 | 3258 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2017 | 1375 | 0.090 |
Why?
|
Medical Oncology | 1 | 2021 | 2313 | 0.090 |
Why?
|
Anxiety | 5 | 2023 | 4538 | 0.090 |
Why?
|
DNA Damage | 1 | 2019 | 2442 | 0.080 |
Why?
|
Metabolomics | 1 | 2018 | 1628 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13262 | 0.080 |
Why?
|
Glycosaminoglycans | 1 | 2012 | 605 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 878 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3388 | 0.080 |
Why?
|
Time Factors | 3 | 2020 | 40165 | 0.080 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2018 | 3765 | 0.080 |
Why?
|
Child | 10 | 2024 | 79806 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7233 | 0.080 |
Why?
|
Dendritic Cells | 1 | 2019 | 2725 | 0.080 |
Why?
|
Ambulatory Care Facilities | 1 | 2014 | 926 | 0.070 |
Why?
|
Cause of Death | 2 | 2021 | 3725 | 0.070 |
Why?
|
Databases, Factual | 4 | 2018 | 8035 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12159 | 0.070 |
Why?
|
Emergencies | 1 | 2014 | 1211 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1174 | 0.070 |
Why?
|
Mitochondria | 2 | 2019 | 3600 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2932 | 0.070 |
Why?
|
DNA Methylation | 2 | 2018 | 4373 | 0.070 |
Why?
|
Stress, Mechanical | 1 | 2012 | 1666 | 0.070 |
Why?
|
Rabbits | 2 | 2012 | 4773 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5397 | 0.070 |
Why?
|
Genetic Variation | 2 | 2021 | 6551 | 0.070 |
Why?
|
Sarcoma | 1 | 2017 | 1786 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 2128 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 916 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2532 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2019 | 3736 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1152 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2017 | 1939 | 0.060 |
Why?
|
Odds Ratio | 2 | 2020 | 9716 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5425 | 0.060 |
Why?
|
Medicare | 1 | 2023 | 6786 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 4981 | 0.060 |
Why?
|
Population Surveillance | 1 | 2015 | 2608 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2501 | 0.060 |
Why?
|
Cartilage, Articular | 1 | 2012 | 1091 | 0.060 |
Why?
|
Disease Progression | 2 | 2021 | 13502 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 3880 | 0.060 |
Why?
|
Consensus | 2 | 2024 | 3113 | 0.060 |
Why?
|
Apoptosis | 1 | 2019 | 9501 | 0.060 |
Why?
|
Stroke Volume | 1 | 2017 | 5523 | 0.060 |
Why?
|
Hospitalization | 2 | 2021 | 10790 | 0.050 |
Why?
|
Prospective Studies | 4 | 2021 | 54303 | 0.050 |
Why?
|
Cohort Studies | 6 | 2021 | 41335 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5794 | 0.050 |
Why?
|
Depression | 4 | 2023 | 8044 | 0.050 |
Why?
|
Caregivers | 1 | 2014 | 2224 | 0.050 |
Why?
|
Weight Gain | 1 | 2012 | 2347 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 158 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18137 | 0.040 |
Why?
|
Boron Compounds | 1 | 2022 | 180 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15840 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5799 | 0.040 |
Why?
|
Animals | 6 | 2023 | 167963 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1039 | 0.040 |
Why?
|
Logistic Models | 3 | 2020 | 13314 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 3986 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4899 | 0.040 |
Why?
|
Pediatrics | 1 | 2014 | 3586 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11152 | 0.040 |
Why?
|
Glycine | 1 | 2022 | 662 | 0.040 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2017 | 58 | 0.040 |
Why?
|
Thiotepa | 1 | 2017 | 66 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1650 | 0.040 |
Why?
|
Prednisolone | 1 | 2018 | 327 | 0.040 |
Why?
|
Neutropenia | 1 | 2022 | 884 | 0.040 |
Why?
|
Primary Health Care | 1 | 2014 | 4647 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10827 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 936 | 0.040 |
Why?
|
Death | 1 | 2021 | 678 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 283 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1764 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 2018 | 482 | 0.030 |
Why?
|
Sepsis | 1 | 2011 | 2592 | 0.030 |
Why?
|
Busulfan | 1 | 2017 | 258 | 0.030 |
Why?
|
Erythroblasts | 1 | 1977 | 143 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2022 | 11071 | 0.030 |
Why?
|
Reticulocytes | 1 | 1977 | 288 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2020 | 1600 | 0.030 |
Why?
|
Palliative Care | 2 | 2021 | 3607 | 0.030 |
Why?
|
Marital Status | 1 | 2017 | 433 | 0.030 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 130 | 0.030 |
Why?
|
Sample Size | 1 | 2018 | 840 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2023 | 1974 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5889 | 0.030 |
Why?
|
Child, Preschool | 4 | 2018 | 42063 | 0.030 |
Why?
|
International Cooperation | 1 | 2021 | 1433 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1613 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7818 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1722 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2022 | 4107 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5253 | 0.030 |
Why?
|
Comorbidity | 2 | 2018 | 10551 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6659 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4035 | 0.030 |
Why?
|
Random Allocation | 1 | 2017 | 2394 | 0.030 |
Why?
|
Benchmarking | 1 | 2019 | 1044 | 0.030 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2014 | 286 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2017 | 2116 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14495 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2421 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 643 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2021 | 2566 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2932 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1195 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 2897 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2017 | 2221 | 0.020 |
Why?
|
Dioxygenases | 1 | 2014 | 335 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2017 | 843 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8803 | 0.020 |
Why?
|
Hemoglobins | 1 | 1977 | 1521 | 0.020 |
Why?
|
Fetal Blood | 1 | 1977 | 1343 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2916 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8555 | 0.020 |
Why?
|
Educational Status | 1 | 2017 | 2515 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 1999 | 0.020 |
Why?
|
Income | 1 | 2017 | 1875 | 0.020 |
Why?
|
Social Class | 1 | 2017 | 2005 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 806 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2049 | 0.020 |
Why?
|
Erythrocytes | 1 | 1977 | 2415 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12960 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4283 | 0.020 |
Why?
|
Infant | 2 | 2018 | 36060 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3562 | 0.020 |
Why?
|
Poverty | 1 | 2017 | 2695 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3242 | 0.020 |
Why?
|
Spleen | 1 | 2011 | 2298 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3925 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2022 | 7475 | 0.010 |
Why?
|
Alleles | 1 | 2015 | 6898 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6538 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10547 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5325 | 0.010 |
Why?
|
Medicaid | 1 | 2017 | 2815 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3616 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5496 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4490 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12922 | 0.010 |
Why?
|
Liver | 1 | 1977 | 7509 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25942 | 0.010 |
Why?
|
Genome, Human | 1 | 2014 | 4417 | 0.010 |
Why?
|
Models, Biological | 1 | 2017 | 9467 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3758 | 0.010 |
Why?
|
Registries | 1 | 2014 | 8469 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 26181 | 0.010 |
Why?
|
Polyribosomes | 1 | 1977 | 109 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9585 | 0.010 |
Why?
|
Iron | 1 | 1977 | 1786 | 0.000 |
Why?
|
Gestational Age | 1 | 1977 | 3565 | 0.000 |
Why?
|